Skip to main content
Figure 1 | Genetic Vaccines and Therapy

Figure 1

From: A combination of intradermal jet-injection and electroporation overcomes in vivodose restriction of DNA vaccines

Figure 1

Impact of DNA vaccine dose and id delivery devices on immunogenicity. BALB/c mice were immunized week 0 and 4 with pKCMVp37B with either Biojector (BJ) or with needle followed by electroporation (EP). For Biojector, 10, 5 × 200 or 1000 μg DNA was delivered in 100 μl saline/injection. For needle plus EP, 10, 5 × 20 or 100 μg was delivered in 10 μl saline/injection. A) Cellular immune responses were assessed by IFN-γ ELISpot on splenocytes collected two weeks after the second immunization. A peptide pool representing Gag p24B was used to stimulate splenocytes. B) Binding antibodies to Gagp17/p24B were addressed by ELISA on serum collected two weeks post the last immunization. Bars represent mean values. *Significant difference (p < 0.05). ns = no significant difference.

Back to article page